How Much Missing May Be Too Much in Clinical Trials of Neuropharmacological Drug Products

ISSN： 2213-476X

Source： Applied Clinical Research, Clinical Trials and Regulatory Affairs, Vol.1, Iss.3, 2014-12, pp. : 125-134

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

How Much Is Too Much?

By COLEMAN WILLIAM P.

Dermatologic Surgery, Vol. 22, Iss. 11, 1996-11 ,pp. : 978-978

Elsevier

Access to resources Recommend Favorite

Exercise and vascular function: how much is too much?

By Durand Matthew J. Gutterman David D.

Canadian Journal of Physiology and Pharmacology, Vol. 92, Iss. 7, 2014-01 ,pp. : 551-557

NRC Research Press

Access to resources Recommend Favorite

Commentary: How Much Is Too Much? Tourniquets and Digital Ischemia

By Jellinek Nathaniel J.

Dermatologic Surgery, Vol. 39, Iss. 4, 2013-04 ,pp. : 593-595

Elsevier

Access to resources Recommend Favorite

How much is patent protection threatened by drug costs?

By Loff Bebe

Expert Opinion on Pharmacotherapy, Vol. 5, Iss. 9, 2004-09 ,pp. : 1863-1865

Informa Healthcare

Access to resources Recommend Favorite

How much for a star? Elements for a rational choice of sample size in preclinical trials

By Haimez C. Groupe Biopharmacie et Sante de la Societe Francaise de Statistique Good preclinical statistical practices working party

Trends in Pharmacological Sciences, Vol. 23, Iss. 5, 2002-05 ,pp. : 221-225

Elsevier

Access to resources Recommend Favorite